Vistagen Therapeutics, Inc. (VTGN)

Vistagen Therapeutics' stock has experienced significant volatility and negative impacts. The PALISADE-3 Phase 3 study of intranasal fasedienol did not achieve its primary endpoint, leading to a dramatic decline in the stock price. Several securities class-action lawsuits have been filed against Vistagen Therapeutics, alleging that the company made materially false and misleading statements regarding the development and prospects of fasedienol. The stock's weekly volatility has also increased.

Information regarding demand seasonality for Vistagen Therapeutics, Inc.'s products and services is not publicly available. The company is a clinical-stage biopharmaceutical company, and its products are still in development, meaning commercial demand seasonality would not yet be a primary factor.

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on pioneering neuroscience, targeting neuropsychiatric and neurological disorders. Vistagen leverages a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates known as pherines. Fasedienol is in Phase III clinical development for social anxiety disorder. Itruvone is in Phase II clinical trials for major depressive disorder. PH80 is in Phase II clinical trials for vasomotor symptoms. PH15 is in Phase II clinical trials to improve cognitive impairment. PH284 is in Phase II clinical trials to treat loss of appetite. AV-101 is an oral prodrug that targets the NMDA receptor for treating depression and neurological disorders.

Vistagen Therapeutics, Inc. is headquartered in South San Francisco, California. Fasedienol is undergoing a U.S. registration-directed Phase III clinical development program. Vistagen also has a license and collaboration agreement with AffaMed Therapeutics, Inc. for the development, manufacture, and commercialization of fasedienol.

Vistagen Therapeutics' brand reputation has been significantly impacted by the failure of its PALISADE-3 Phase 3 clinical trial for Fasedienol and the subsequent class-action lawsuits. The trial's failure and the lawsuits have likely damaged investor confidence and public perception. The company's stock underperformed both the US Biotechs industry and the broader US Market, reflecting negatively on its reputation.

Major institutional owners of Vistagen Therapeutics, Inc. include Janus Henderson Group Plc, Orbimed Advisors Llc, TCG Crossover Management, LLC, StemPoint Capital LP, Nantahala Capital Management, LLC, Vanguard Group Inc, Commodore Capital Lp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Ikarian Capital, LLC, and Soleus Capital Management, L.P. Other notable institutional holders include JPMorgan Chase & Co., Millennium Management LLC, Bank of America Corp DE, Boothbay Fund Management LLC, Schonfeld Strategic Advisors LLC, Occudo Quantitative Strategies LP, ADAR1 Capital Management LLC, Two Sigma Investments LP, Blair William & Co. IL, and Dimensional Fund Advisors LP. Individual/insider ownership accounts for 0.27% of the shares outstanding.